---
title: "Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285371618.md"
description: "Stifel Nicolaus analyst Annabel Samimy has maintained a Buy rating on Trevi Therapeutics (TRVI) with a price target of $18.00. The analyst has an average return of 17.1% and a success rate of 50.79% on her stock recommendations. The overall analyst consensus for Trevi Therapeutics is a Strong Buy, with an average price target of $22.14."
datetime: "2026-05-06T11:46:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285371618.md)
  - [en](https://longbridge.com/en/news/285371618.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285371618.md)
---

# Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

In a report released today, Annabel Samimy from Stifel Nicolaus reiterated a Buy rating on Trevi Therapeutics, with a price target of $18.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Samimy covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, Viking Therapeutics, and RegenXBio. According to TipRanks, Samimy has an average return of 17.1% and a 50.79% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Trevi Therapeutics with a $22.14 average price target.

### Related Stocks

- [TRVI.US](https://longbridge.com/en/quote/TRVI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)
- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Research Analysts Set Expectations for TRVI FY2030 Earnings](https://longbridge.com/en/news/285552816.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program](https://longbridge.com/en/news/287222906.md)